1 / 24

Personalized medicine and oncosurgery

Personalized medicine and oncosurgery. O .Topolčan, V. Třeška. Teaching Hospital Plzeň, Faculty of Medicine in Plzeň, Charles University in Prague Czech Republic. Presentation structure. Personalized medicine and cancer Clinical use of biomarke r s assessment Our results

allie
Download Presentation

Personalized medicine and oncosurgery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Personalized medicine and oncosurgery O.Topolčan, V. Třeška Teaching Hospital Plzeň, Faculty of Medicine in Plzeň, Charles University in PragueCzech Republic

  2. Presentation structure • Personalizedmedicineandcancer • Clinical use of biomarkers assessment • Our results • Conclusions for clinical practice • Final goal

  3. Todays x personalized • Todaysdiagnostics • Fromsymptoms to diagnosis • Empiricorcausaltherapy Personalizedmedicine • Moleculardiagnostic – biomarkers, genomic, • - omixmethod • Therapystratifed - individualised

  4. Impact of MolecularDiagnostics on theManegement of Cancer • Clasficacation of cancer • Risk assesmentandprognosis • Prediction of response to treatment • Guide to therapeutics

  5. Clasification of cancer • Analysis of RNA splicingevent in cancer • Cancerclassificationusingmicroarrays • Cancerstratificationbased on methlation markers • Analysis of chromosomalalteration of cancercells • Detection of loss of hererozigosity (LOH) • Diagnosis of cancer of anunkownprimary • Diagnosticsfordetection of minimalresidualdisease

  6. Risk asesmentandprognosis • Cancerprognosis • Detection of mutationsfor risk asessmetandprevention

  7. Prediction of responce to treatment • Biopsytesting of tumorsforchemotherapy sensitivity • Genomicanalysis of tumor biopsies to predict response to treatment • Serumnucleosides as indicators of sensitivity as chemotherapy • Testingmicrosatelliteinstabililityforrespose to chemotherapy • Prediction of response to radiationtherapy

  8. Guide to therapeutics • Diagnosticsfordetection of Multidrugresistency • Detection of resistence to chemotherapy • Moleculardiagnosticscombinedwithcancertherapeutics • Drugdiscoveryanddevelopment • Design of futurecancertherapies • Screeningforpersonalizedanticancerdrug • Pharmacogenomic test forstratification of clinicaltrials

  9. Current status • Routine • Biomarkers = tumor markers • High PPV, Low NPV, Low sensitivity andspecicifity • Indication • Follow-up of cancer disease

  10. Ourreults Metastatic proces in Liver

  11. New ourapproachforClinical use of biomarkers • Targetquestionandtargetbiomarkers • Multidiscplinedapproach • Multiparametrdiagnostics • Multiplex andOptimal therapy choice of surgery procedure

  12. Metastasisresection • Preoperativandpooperativfor prognosis: • Tumor markers CEA, CA 19-9, cytokeratins, • AngiogenoticfactorOPR, OPN, PRL, VEGF, • GrowthfactorHGF, IGF -1, IGFBP 3, 7 • MMP 7, 9 TIMP-1 • Gene expression K-ras, p53, HER-2 neu, TIMP-1, MMP 7, 9 Predictionforprogresion • CEA, circulating cancer cells or circulating DNA • D vitamine

  13. RFA • Preoperativandpooperativfor prognosis: • Tumor markers CEA, CA 19-9, cytokeratins, • AngiogenoticfactorOPR, OPN, PRL, VEGF, • GrowthfactorHGF, IGF -1, IGFBP 3, 7 • MMP 7, 9 TIMP-1 • Gene expression K-ras, p53, HER-2 neu, TIMP-1, MMP 7, 9 Predictionforprogresion • CEA, circulating cancer cells or circulating DNA • D vitamine cytokeratine

  14. Portalveinembolism • Aimfor vyšetření – predictterapeuticeffect • goodresponce – regeneration • poorresponce - minimalgrowth • Tumor progresion

  15. Portalveinembolism • Imaing technik – expensiv, slowchangis • Markes – research – in ourlaboratory • Cytokeratins • Cytokains – inflamatory IL • Angiogenetics – OPG, OPN • Growth IGF-1

  16. IGF -1 • Anti-apoptotic activity • Mitotic activity • MMP-7 activation • IGFBP3 inhibition • Correlation between IGF1 and Multidrug Resistance-Associated Protein-1 (MDR -1) • Inverse correlation with adiponectin

  17. Adiponectin • Breast cancer • MMP-7 inhibition, favorable prognosis • Anti-angiogenetic effect • Gastric cancer • Angiogenesis inhibition, • apoptosis activation, favorable prognosis • Prostate cancer • Controversial results

  18. Prolactin • Angiogenesis stimulation • Adhesion molecules stimulation • Metastatic potentiating of tumor • CRC - unfavorable prognosis

  19. Why do we need this knowledge • Prevention • Diagnostics • Prognosis estimation • Follow-up • Therapy • Optimal therapy choice • New therapy choice – personalized medicine

  20. Prevention Targeted prevention • Active screening of patients for the risk of cancer occurence • Stratificationpopulation • Targeted prevention method • Targeted prevention monitoring

  21. Diagnosis ! Not (so far) ? Hopefully in future ??

  22. Prognosis a prediction • Prognosis preoprativfor DFI and OS • Prediction of surgeryeffectfordiferent type operationion • Residual • Postoperativchekingandprognosisfor DFI and OS • Follow-upandpredictionrelaps • Early detection of disease progression

  23. Final goal • Improvement to the quality of life of cancer patients • DFI and OS extension

  24. Thank you for your attention

More Related